News & Insights
Key Takeaways
- Allogeneic cell therapies offer cost and efficiency advantages by decoupling manufacturing from individual patients, enabling faster availability and simpler logistics.
- Automation in cell therapy manufacturing enhances consistency, reduces user error, and lowers training barriers, crucial for scaling up production.
- Flexible manufacturing processes must balance regulatory requirements with the need for adaptability as therapies progress through clinical trials.
- CDMOs are essential in addressing evolving manufacturing needs, offering expertise in diverse platforms and processes for both autologous and allogeneic therapies.
Check out the full article at BioPharm International.
